Liposomal benzoporphyrin derivative verteporfin photodynamic therapy: Selective treatment of choroidal neovascularization in monkeys

M. Kramer, J. W. Miller, N. Michaud, R. S. Moulton, T. Hasan, Thomas J Flotte, E. S. Gragoudas

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

Purpose: The authors have previously shown that photodynamic therapy (PDT) using lipoprotein-delivered benzoporphyrin derivative mono-acid (BPD) effectively closed experimental choroidal neovascularization (CNV). In the current study, the authors used a clinical preparation, liposomal BPD verteporfin in the same model, with experiments designed to establish optimal dye and light doses, and the timing of laser light irradiation after dye injection, for effective and selective closure of CNV. Methods: Experimental CNV was induced in the maculae of cynomolgus monkeys. Liposomal BPD verteporfin was injected intravenously at doses of 1.0, 0.5, 0.375, and 0.25 mg/kg. Laser light at 692 nm then was applied to CNV, with an irradiance of 600 mW/cm2 and fluence of 150 J/cm2, at various times after dye injection, ranging from 5 to 120 minutes. Treatment effect was assessed by fundus photography and fluorescein angiography and confirmed by light and electron microscopy. The PDT of experimental CNV was studied to assess efficacy; PDT performance on normal eyes was studied to investigate selectivity. Results: The CNV closure was demonstrated by fluorescein angiography and histopathologic findings at all tested dye doses. A dye dose of 0.375 mg/kg, with laser light irradiation applied 20 to 50 minutes after dye injection, optimized CNV closure with minimal retinal and choroidal damage. No major local adverse effects were noted, and the drug was well tolerated systematically. Conclusions: Liposomal BPD verteporfin is a potent photosensitizer, and PDT using this dye is a potentially effective and selective treatment for CNV.

Original languageEnglish (US)
Pages (from-to)427-438
Number of pages12
JournalOphthalmology
Volume103
Issue number3
StatePublished - 1996
Externally publishedYes

Fingerprint

Choroidal Neovascularization
Photochemotherapy
Haplorhini
Coloring Agents
Light
Lasers
Acids
Fluorescein Angiography
Therapeutics
Injections
Photosensitizing Agents
Macaca fascicularis
verteporfin
Photography
Lipoproteins
Electron Microscopy

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Kramer, M., Miller, J. W., Michaud, N., Moulton, R. S., Hasan, T., Flotte, T. J., & Gragoudas, E. S. (1996). Liposomal benzoporphyrin derivative verteporfin photodynamic therapy: Selective treatment of choroidal neovascularization in monkeys. Ophthalmology, 103(3), 427-438.

Liposomal benzoporphyrin derivative verteporfin photodynamic therapy : Selective treatment of choroidal neovascularization in monkeys. / Kramer, M.; Miller, J. W.; Michaud, N.; Moulton, R. S.; Hasan, T.; Flotte, Thomas J; Gragoudas, E. S.

In: Ophthalmology, Vol. 103, No. 3, 1996, p. 427-438.

Research output: Contribution to journalArticle

Kramer, M, Miller, JW, Michaud, N, Moulton, RS, Hasan, T, Flotte, TJ & Gragoudas, ES 1996, 'Liposomal benzoporphyrin derivative verteporfin photodynamic therapy: Selective treatment of choroidal neovascularization in monkeys', Ophthalmology, vol. 103, no. 3, pp. 427-438.
Kramer, M. ; Miller, J. W. ; Michaud, N. ; Moulton, R. S. ; Hasan, T. ; Flotte, Thomas J ; Gragoudas, E. S. / Liposomal benzoporphyrin derivative verteporfin photodynamic therapy : Selective treatment of choroidal neovascularization in monkeys. In: Ophthalmology. 1996 ; Vol. 103, No. 3. pp. 427-438.
@article{e1e497e660fc4fb7b78e158666dff5d4,
title = "Liposomal benzoporphyrin derivative verteporfin photodynamic therapy: Selective treatment of choroidal neovascularization in monkeys",
abstract = "Purpose: The authors have previously shown that photodynamic therapy (PDT) using lipoprotein-delivered benzoporphyrin derivative mono-acid (BPD) effectively closed experimental choroidal neovascularization (CNV). In the current study, the authors used a clinical preparation, liposomal BPD verteporfin in the same model, with experiments designed to establish optimal dye and light doses, and the timing of laser light irradiation after dye injection, for effective and selective closure of CNV. Methods: Experimental CNV was induced in the maculae of cynomolgus monkeys. Liposomal BPD verteporfin was injected intravenously at doses of 1.0, 0.5, 0.375, and 0.25 mg/kg. Laser light at 692 nm then was applied to CNV, with an irradiance of 600 mW/cm2 and fluence of 150 J/cm2, at various times after dye injection, ranging from 5 to 120 minutes. Treatment effect was assessed by fundus photography and fluorescein angiography and confirmed by light and electron microscopy. The PDT of experimental CNV was studied to assess efficacy; PDT performance on normal eyes was studied to investigate selectivity. Results: The CNV closure was demonstrated by fluorescein angiography and histopathologic findings at all tested dye doses. A dye dose of 0.375 mg/kg, with laser light irradiation applied 20 to 50 minutes after dye injection, optimized CNV closure with minimal retinal and choroidal damage. No major local adverse effects were noted, and the drug was well tolerated systematically. Conclusions: Liposomal BPD verteporfin is a potent photosensitizer, and PDT using this dye is a potentially effective and selective treatment for CNV.",
author = "M. Kramer and Miller, {J. W.} and N. Michaud and Moulton, {R. S.} and T. Hasan and Flotte, {Thomas J} and Gragoudas, {E. S.}",
year = "1996",
language = "English (US)",
volume = "103",
pages = "427--438",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Liposomal benzoporphyrin derivative verteporfin photodynamic therapy

T2 - Selective treatment of choroidal neovascularization in monkeys

AU - Kramer, M.

AU - Miller, J. W.

AU - Michaud, N.

AU - Moulton, R. S.

AU - Hasan, T.

AU - Flotte, Thomas J

AU - Gragoudas, E. S.

PY - 1996

Y1 - 1996

N2 - Purpose: The authors have previously shown that photodynamic therapy (PDT) using lipoprotein-delivered benzoporphyrin derivative mono-acid (BPD) effectively closed experimental choroidal neovascularization (CNV). In the current study, the authors used a clinical preparation, liposomal BPD verteporfin in the same model, with experiments designed to establish optimal dye and light doses, and the timing of laser light irradiation after dye injection, for effective and selective closure of CNV. Methods: Experimental CNV was induced in the maculae of cynomolgus monkeys. Liposomal BPD verteporfin was injected intravenously at doses of 1.0, 0.5, 0.375, and 0.25 mg/kg. Laser light at 692 nm then was applied to CNV, with an irradiance of 600 mW/cm2 and fluence of 150 J/cm2, at various times after dye injection, ranging from 5 to 120 minutes. Treatment effect was assessed by fundus photography and fluorescein angiography and confirmed by light and electron microscopy. The PDT of experimental CNV was studied to assess efficacy; PDT performance on normal eyes was studied to investigate selectivity. Results: The CNV closure was demonstrated by fluorescein angiography and histopathologic findings at all tested dye doses. A dye dose of 0.375 mg/kg, with laser light irradiation applied 20 to 50 minutes after dye injection, optimized CNV closure with minimal retinal and choroidal damage. No major local adverse effects were noted, and the drug was well tolerated systematically. Conclusions: Liposomal BPD verteporfin is a potent photosensitizer, and PDT using this dye is a potentially effective and selective treatment for CNV.

AB - Purpose: The authors have previously shown that photodynamic therapy (PDT) using lipoprotein-delivered benzoporphyrin derivative mono-acid (BPD) effectively closed experimental choroidal neovascularization (CNV). In the current study, the authors used a clinical preparation, liposomal BPD verteporfin in the same model, with experiments designed to establish optimal dye and light doses, and the timing of laser light irradiation after dye injection, for effective and selective closure of CNV. Methods: Experimental CNV was induced in the maculae of cynomolgus monkeys. Liposomal BPD verteporfin was injected intravenously at doses of 1.0, 0.5, 0.375, and 0.25 mg/kg. Laser light at 692 nm then was applied to CNV, with an irradiance of 600 mW/cm2 and fluence of 150 J/cm2, at various times after dye injection, ranging from 5 to 120 minutes. Treatment effect was assessed by fundus photography and fluorescein angiography and confirmed by light and electron microscopy. The PDT of experimental CNV was studied to assess efficacy; PDT performance on normal eyes was studied to investigate selectivity. Results: The CNV closure was demonstrated by fluorescein angiography and histopathologic findings at all tested dye doses. A dye dose of 0.375 mg/kg, with laser light irradiation applied 20 to 50 minutes after dye injection, optimized CNV closure with minimal retinal and choroidal damage. No major local adverse effects were noted, and the drug was well tolerated systematically. Conclusions: Liposomal BPD verteporfin is a potent photosensitizer, and PDT using this dye is a potentially effective and selective treatment for CNV.

UR - http://www.scopus.com/inward/record.url?scp=0029864913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029864913&partnerID=8YFLogxK

M3 - Article

C2 - 8600419

AN - SCOPUS:0029864913

VL - 103

SP - 427

EP - 438

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 3

ER -